The neurobiology of the switch process in bipolar disorder: A review

Journal of Clinical Psychiatry

Volumn 71, Issue 11, 2010, Pages 1488-1501

  Salvadore, Giacomo ^a   Quiroz, Jorge A ^c   Machado Vieira, Rodrigo ^a   Henter, Ioline D ^a   Manji, Husseini K ^b   Zarate Jr , Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Roche Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; CATECHOLAMINE; CITALOPRAM; DESIPRAMINE; DEXAMPHETAMINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; KETAMINE; LAMOTRIGINE; LEVODOPA; LITHIUM; METHYLDOPA; MK 485; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROTROPHIC FACTOR; OLANZAPINE; PAROXETINE; PLACEBO; PSYCHOSTIMULANT AGENT; REBOXETINE; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ADD ON THERAPY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CIRCADIAN RHYTHM; CLINICAL FEATURE; CLINICAL TRIAL; DATA BASE; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG WITHDRAWAL; HUMAN; HYPERACTIVITY; HYPOMANIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFORMATION RETRIEVAL; MANIA; MEDICAL LITERATURE; MENTAL DISEASE; MOOD CHANGE; NERVE CELL PLASTICITY; NEUROBIOLOGY; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SLEEP DEPRIVATION; TREATMENT EMERGENT AFFECTIVE SWITCH;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIPOLAR DISORDER; CIRCADIAN RHYTHM; DOPAMINE AGENTS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RECEPTORS, CATECHOLAMINE; SEROTONIN UPTAKE INHIBITORS; SLEEP DEPRIVATION; TETRAHYDROCANNABINOL;

EID: 78049456368     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09r05259gre     Document Type: Review

References (157)

1. Falret J. Mémoire sur la folie circulaire, forme de maladie mentale caractérisée par la reproduction sucessive et réguliäre de l'état maniqaue, de l'état mélancolique, et d'un intervalle lucide plus or moins prolongé. Bull Acad Natl Med. 1854;19:382-415.
2. Sedler MJ. Falret's discovery: the origin of the concept of bipolar affective illness. Sedler MJ, Dessain EC, trans. Am J Psychiatry. 1983;140(9):1127-1133.
3. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry. 2000;48(6):445-457.
4. Angst J. Switch from depression to mania, or from mania to depression: role of psychotropic drugs. Psychopharmacol Bull. 1987;23(1):66-67.
5. Licht RW, Gijsman H, Nolen WA, et al. Are antidepressants safe in the treatment of bipolar depression? a critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand. 2008;118(5):337-346.
6. Grunze HC. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr. 2008;13(9):790-795.
7. Hasler G, Drevets WC, Gould TD, et al. Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry. 2006;60(2):93-105.
8. Benedetti F, Serretti A, Colombo C, et al. Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet B Neuropsychiatr Genet. 2003;123B(1):23-26.
9. Mundo E, Walker M, Cate T, et al. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry. 2001;58(6):539-544.
10. Vieta E, Angst J, Reed C, et al. EMBLEM advisory board. Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM). J Affect Disord. 2009;118(1-3):118-123.
11. MacKinnon DF, Zandi PP, Gershon ES, et al. Association of rapid mood switching with panic disorder and familial panic risk in familial bipolar disorder. Am J Psychiatry. 2003;160(9):1696-1698.
12. MacKinnon DF, Zandi PP, Gershon E, et al. Rapid switching of mood in families with multiple cases of bipolar disorder. Arch Gen Psychiatry. 2003;60(9):921-928.
13. MacKinnon DF, Potash JB, McMahon FJ, et al. National Institutes of Mental Health Bipolar Disorder Genetics Initiative. Rapid mood switching and suicidality in familial bipolar disorder. Bipolar Disord. 2005;7(5):441-448.
14. Maj M, Pirozzi R, Magliano L, et al. The prognostic significance of "switching" in patients with bipolar disorder: a 10-year prospective follow-up study. Am J Psychiatry. 2002;159(10):1711-1717.
15. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152(8):1130-1138.
16. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev. 2007;31(6):858-873.
17. Bottlender R, Sato T, Kleindienst N, et al. Mixed depressive features predict maniform switch during treatment of depression in bipolar I disorder. J Affect Disord. 2004;78(2):149-152.
18. Zarate CA Jr, Tohen M, Fletcher K. Cycling into depression from a first episode of mania: a case-comparison study. Am J Psychiatry. 2001;158(9):1524- 1526.
19. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-1722.
20. Serretti A, Artioli P, Zanardi R, et al. Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(5):751-757.
21. Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry. 2001;62(4):249-255.
22. Truman CJ, Goldberg JF, Ghaemi SN, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry. 2007;68(10):1472-1479.
23. Carlson GA, Finch SJ, Fochtmann LJ, et al. Antidepressant-associated switches from depression to mania in severe bipolar disorder. Bipolar Disord. 2007;9(8):851-859.
24. Tamada RS, Issler CK, Amaral JA, et al. Treatment emergent affective switch: a controlled study. Bipolar Disord. 2004;6(4):333-337.
25. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189(2):124-131.
26. El-Mallakh RS, Ghaemi SN, Sagduyu K, et al. STEP-BD Investigators. Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord. 2008;111(2-3):372-377.
27. Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry. 2006; 163(2):313-315.
28. Bauer M, Rasgon N, Grof P, et al. Do antidepressants influence mood patterns? a naturalistic study in bipolar disorder. Eur Psychiatry. 2006;21(4):262-269.
29. Bond DJ, Noronha MM, Kauer-Sant'Anna M, et al. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2008;69(10):1589-1601.
30. Ghaemi SN, Goodwin FK. Antidepressants for bipolar depression. Am J Psychiatry. 2005;162(8):1545-1546, author reply 1547-1548.
31. Salvi VFA, Fagiolini A, Swartz HA, et al. The use of antidepressants in bipolar disorder. J Clin Psychiatry. 2008;69(8):1307-1318.
32. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537-1547.
33. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164(4):549-550.
34. Boerlin HL, Gitlin MJ, Zoellner LA, et al. Bipolar depression and antidepressant-induced mania: a naturalistic study. J Clin Psychiatry. 1998;59(7):374-379.
35. Bunney WE Jr, Murphy DL, Goodwin FK, et al. The switch process from depression to mania: relationship to drugs which alter brain amines. Lancet. 1970;1(7655):1022-1027.
36. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry. 1979;36(5):555-559.
37. Bottlender R, Rudolf D, Strauss A, et al. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord. 2001;63(1-3):79-83.
38. Lewis JL, Winokur G. The induction of mania: a natural history study with controls. Arch Gen Psychiatry. 1982;39(3):303-306.
39. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906-912.
40. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148(7):910-916.
41. Silverstone T. Moclobemide vs imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand. 2001;104(2):104-109.
42. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989;4(4):313-322.
43. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994;55(9): 391-393.
44. Vieta E, Colom F, Martínez-Arán A, et al. Reboxetine-induced hypomania. J Clin Psychiatry. 2001;62(8):655-656.
45. Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand. 2007;115(5):360-365.
46. Wright G, Galloway L, Kim J, et al. Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects. J Clin Psychiatry. 1985;46(1):22-25.
47. Shopsin B. Bupropion's prophylactic efficacy in bipolar affective illness. J Clin Psychiatry. 1983;44(5 Pt 2):163-169.
48. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002;4(3):207-213.
49. Joffe RT, MacQueen GM, Marriott M, et al. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand. 2002;105(6):427-430.
50. Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry. 2002;63(6):508-512.
51. Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol. 2008;28(2):171-181.
52. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression - lack of manic induction. J Affect Disord. 2005;87(1):121-130.
53. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088.
54. Fonseca M, Soares JC, Hatch JP, et al. An open trial of adjunctive escitalopram in bipolar depression. J Clin Psychiatry. 2006;67(1):81-86.
55. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord. 2006;96(1-2):95-99.
56. Rousseva A, Henry C, van den Bulke D, et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J. 2003;3(2):101-104.
57. Serretti A, Artioli P, Zanardi R, et al. Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl). 2004;174(4):504-511.
58. Hughes JH, Dunne F, Young AH. Effects of acute tryptophan depletion on mood and suicidal ideation in bipolar patients symptomatically stable on lithium. Br J Psychiatry. 2000;177(5):447-451.
59. Bunney WE Jr, Goodwin FK, Murphy DL, et al. The "switch process" in manic-depressive illness, II: relationship to catecholamines, REM sleep, and drugs. Arch Gen Psychiatry. 1972;27(3):304-309.
60. Zis AP, Cowdry RW, Wehr TA, et al. Tricyclic-induced mania and MHPG excretion. Psychiatry Res. 1979;1(1):93-99.
61. Joyce PR, Fergusson DM, Woollard G, et al. Urinary catecholamines and plasma hormones predict mood state in rapid cycling bipolar affective disorder. J Affect Disord. 1995;33(4):233-243.
62. Paul MI, Cramer H, Bunney WE Jr. Urinary adenosine 3′,5′- monophosphate in the switch process from depression to mania. Science. 1971;171(968):300-303.
63. Juckel G, Hegerl U, Mavrogiorgou P, et al. Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment. J Clin Psychiatry. 2000;61(8):585-593.
64. Post RM, Stoddard FJ, Gillin JC, et al. Alterations in motor activity, sleep, and biochemistry in a cycling manic-depressive patient. Arch Gen Psychiatry. 1977;34(4):470-477.
65. Jones FD, Maas JW, Dekirmenjian H, et al. Urinary catecholamine metabolites during behavioral changes in a patient with manic-depressive cycles. Science. 1973;179(70):300-302.
66. Bunney WE Jr, Goodwin FK, Murphy DL. The "switch process" in manic-depressive illness, 3: theoretical implications. Arch Gen Psychiatry. 1972;27(3):312-317.
67. Serretti A, Lilli R, Smeraldi E. Pharmacogenetics in affective disorders. Eur J Pharmacol. 2002;438(3):117-128.
68. Pryor JC, Sulser F. Evolution of monoamine hypotheses of depression. In: Horton RW, Katona C, eds. Biological Aspects of Affective Disorders. London, United Kingdom: Academic Press; 1991:77-94.
69. de Montigny C, Chaput Y, Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry. 1990;51(suppl B):4-8.
70. Butkerait P, Wang HY, Friedman E. Increases in guanine nucleotide binding to striatal G proteins is associated with dopamine receptor supersensitivity. J Pharmacol Exp Ther. 1994;271(1):422-428.
71. Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry. 2006;59(11):1006-1020.
72. Du J, Creson TK, Wu LJ, et al. The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci. 2008;28(1):68-79.
73. Shaltiel G, Maeng S, Malkesman O, et al. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry. 2008;13(9):858-872.
74. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol. 2003;23(5):484-495.
75. Calabrese JR, Rapport DJ, Kimmel SE, et al. Controlled trials in bipolar I depression: focus on switch rates and efficacy. Eur Neuropsychopharmacol. 1999;9(suppl 4):S109-S112.
76. Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57(4):430-432.
77. Teng CT, Demetrio FN. Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder. Rev Bras Psiquiatr. 2006;28(3):252-254.
78. Krystal JH, Perry EB Jr, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005;62(9): 985-994.
79. Murphy DL, Brodie HK, Goodwin FK, et al. Regular induction of hypomania by L-dopa in "bipolar" manic-depressive patients. Nature. 1971;229(5280):135-136.
80. Asghar SJ, Tanay VA, Baker GB, et al. Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers. Hum Psychopharmacol. 2003;18(4): 291-299.
81. Jacobs D, Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med. 1986;16(2):323-329.
82. Masand PS, Pickett P, Murray GB. Hypomania precipitated by psychostimulant use in depressed medically ill patients. Psychosomatics. 1995;36(2):145-147.
83. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry. 2001;49(2):81-96.
84. Dlugos A, Freitag C, Hohoff C, et al. Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry. 2007;61(11):1296-1305.
85. Lott DC, Kim SJ, Cook EH Jr, et al. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005;30(3):602-609.
86. Anand A, Darnell A, Miller HL, et al. Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. Biol Psychiatry. 1999;45(8):972-978.
87. McTavish SF, McPherson MH, Harmer CJ, et al. Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry. 2001;179(4):356-360.
88. D'Aquila PS, Peana AT, Panin F, et al. Reversal of antidepressant-induced dopaminergic behavioural supersensitivity after long-term chronic imipramine withdrawal. Eur J Pharmacol. 2003;458(1-2): 129-134.
89. Ichikawa J, Meltzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol. 1995;281(3):255-261.
90. Papp M, Klimek V, Willner P. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl). 1994;115(4):441-446.
91. Anisman H, Irwin J, Sklar LS. Deficits of escape performance following catecholamine depletion: implications for behavioral deficits induced by uncontrollable stress. Psychopharmacology (Berl). 1979;64(2):163-170.
92. Machado-Vieira R, Kapczinski F, Soares JC. Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(2):209-224.
93. Shaldubina A, Einat H, Szechtman H, et al. Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm. 2002;109(3):433-440.
94. Eilam D, Szechtman H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol. 1989;161(2-3):151-157.
95. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A. 2004;101(14):5099-5104.
96. Einat H, Manji HK. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry. 2006;59(12):1160-1171.
97. Chen R, Furman CA, Zhang M, et al. Protein kinase C beta is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice. J Pharmacol Exp Ther. 2009;328(3):912-920.
98. Yildiz A, Guleryuz S, Ankerst DP, et al. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008;65(3):255-263.
99. Zarate CA Jr, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007;9(6):561-570.
100. Ritchie EA. Toxic psychosis under cortisone and corticotrophin. J Ment Sci. 1956;102(429):830-837.
101. Clark LD, Quarton GC, Cobb S, et al. Further observations on mental disturbances associated with cortisone and ACTH therapy. N Engl J Med. 1953;249(5):178-183.
102. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord. 1983;5(4): 319-332.
103. Lewis LD, Cochrane GM. Psychosis in a child inhaling budesonide. Lancet. 1983;2(8350):634.
104. Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther. 1972;13(5):694-698.
105. Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology. 1988; 38(10):1631-1634.
106. Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology. 1996;21(1):25-31.
107. Brown ES, Suppes T, Khan DA, et al. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol. 2002;22(1):55-61.
108. Türktaş L, Gücüyener K, Ozden A. Medication-induced psychotic reaction. J Am Acad Child Adolesc Psychiatry. 1997;36(8):1017-1018.
109. Wolkowitz OM, Rubinow D, Doran AR, et al. Prednisone effects on neurochemistry and behavior. Preliminary findings. Arch Gen Psychiatry. 1990;47(10):963-968.
110. Wada K, Yamada N, Suzuki H, et al. Recurrent cases of corticosteroid-induced mood disorder: clinical characteristics and treatment. J Clin Psychiatry. 2000;61(4):261-267.
111. Phelan MC. Beclomethasone mania. Br J Psychiatry. 1989;155(6): 871-872.
112. Goldstein ET, Preskorn SH. Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder. Am J Psychiatry. 1989;146(8):1076-1077.
113. Vacheron-Trystram MN, Cheref S, Gauillard J, et al. [A case report of mania precipitated by use of DHEA]. (Article in French) Encephale. 2002;28(6 Pt 1):563-566.
114. Fishman SM, Catarau EM, Sachs G, et al. Corticosteroid-induced mania after single regional application at the celiac plexus. Anesthesiology. 1996;85(5):1194-1196.
115. Sharfstein SS, Sack DS, Fauci AS. Relationship between alternate-day corticosteroid therapy and behavioral abnormalities. JAMA. 1982;248(22):2987- 2989.
116. Daban C, Vieta E, Mackin P, et al. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am. 2005;28(2):469-480.
117. Krishnan RR, Maltbie AA, Davidson JR. Abnormal cortisol suppression in bipolar patients with simultaneous manic and depressive symptoms. Am J Psychiatry. 1983;140(2):203-205.
118. Swann AC, Stokes PE, Casper R, et al. Hypothalamic-pituitary- adrenocortical function in mixed and pure mania. Acta Psychiatr Scand. 1992;85(4):270-274.
119. Gann H, Riemann D, Hohagen F, et al. 48-hour rapid cycling: results of psychopathometric, polysomnographic, PET imaging and neuroendocrine longitudinal investigations in a single case. J Affect Disord. 1993;28(2):133-140.
120. Doerr P, von Zerssen D, Fischler M, et al. Relationship between mood changes and adrenal cortical activity in a patient with 48-hour unipolardepressive cycles. J Affect Disord. 1979;1(2):93-104.
121. Bunney WE Jr, Hartmann EL, Mason JW. Study of a patient with 48-hour manic-depressive cycles, II: strong positive correlation between endocrine factors and manic defense patterns. Arch Gen Psychiatry. 1965;12:619-625.
122. Wei Q, Lu XY, Liu L, et al. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc Natl Acad Sci U S A. 2004;101(32):11851-11856.
123. Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry. 1987;144(2):201-204.
124. Barbini B, Colombo C, Benedetti F, et al. The unipolar-bipolar dichotomy and the response to sleep deprivation. Psychiatry Res. 1998;79(1): 43-50.
125. Colombo C, Benedetti F, Barbini B, et al. Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Res. 1999;86(3):267-270.
126. Leibenluft E, Albert PS, Rosenthal NE, et al. Relationship between sleep and mood in patients with rapid-cycling bipolar disorder. Psychiatry Res. 1996;63(2-3):161-168.
127. Albert I, Cicala GA, Siegel J. The behavioral effects of REM sleep deprivation in rats. Psychophysiology. 1970;6(5):550-560.
128. Gessa GL, Pani L, Fadda P, et al. Sleep deprivation in the rat: an animal model of mania. Eur Neuropsychopharmacol. 1995;5(suppl):89-93.
129. Hicks RA, Moore JD, Hayes C, et al. REM sleep deprivation increases aggressiveness in male rats. Physiol Behav. 1979;22(6):1097-1100. doi:10.1016/031-9384(79)90263-4 PubMed (Pubitemid 10226605)
130. Moore JD, Hayes C, Hicks RA. REM sleep deprivation increases preference for novelty in rats. Physiol Behav. 1979;23(5):975-976. doi:10.1016/031-9384(79) 9021-7 PubMed (Pubitemid 10211311)
131. Ferraz MR, Ferraz MM, Santos R. How REM sleep deprivation and amantadine affects male rat sexual behavior. Pharmacol Biochem Behav. 2001;69(3-4):325-332.
132. Benedetti F, Fresi F, Maccioni P, et al. Behavioural sensitization to repeated sleep deprivation in a mice model of mania. Behav Brain Res. 2008;187(2):221-227.
133. Siegel JM, Rogawski MA. A function for REM sleep: regulation of noradrenergic receptor sensitivity. Brain Res. 1988;472(3):213-233.
134. Demontis MG, Fadda P, Devoto P, et al. Sleep deprivation increases dopamine D1 receptor antagonist [3H]SCH 23390 binding and dopamine-stimulated adenylate cyclase in the rat limbic system. Neurosci Lett. 1990;117(1-2):224- 227.
135. Schreiber W, Opper C, Dickhaus B, et al. Alterations of blood platelet MAO-B activity and LSD-binding in humans after sleep deprivation and recovery sleep. J Psychiatr Res. 1997;31(3):323-331.
136. Ebert D, Ebmeier KP. The role of the cingulate gyrus in depression: from functional anatomy to neurochemistry. Biol Psychiatry. 1996;39(12):1044-1050.
137. Gerner RH, Post RM, Gillin JC, et al. Biological and behavioral effects of one night's sleep deprivation in depressed patients and normals. J Psychiatr Res. 1979;15(1):21-40.
138. Post RM, Kotin J, Goodwin FK. Effects of sleep deprivation on mood and central amine metabolism in depressed patients. Arch Gen Psychiatry. 1976;33(5):627-632.
139. Cirelli C, Tononi G. Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system. J Neurosci. 2000;20(24):9187-9194.
140. Tononi G, Cirelli C. Modulation of brain gene expression during sleep and wakefulness: a review of recent findings. Neuropsychopharmacology. 2001;25(suppl):S28-S35.
141. Payne JL, Quiroz JA, Zarate CA Jr, et al. Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol Psychiatry. 2002;52(10):921-926.
142. Gillin JCMC, Mazure C, Post RM, et al. An EEG sleep study of a bipolar (manic-depressive) patient with a nocturnal switch process. Biol Psychiatry. 1977;12(6):711-718.
143. Einat H, Manji HK, Gould TD, et al. Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice. Drug News Perspect. 2003;16(7):453-463.
144. Sitaram N, Gillin JC, Bunney WE Jr. The switch process in manic-depressive illness: circadian variation in time of switch and sleep and manic ratings before and after switch. Acta Psychiatr Scand. 1978;58(3):267-278.
145. Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol. 2006;21(suppl 1):S11-S15.
146. Gould TD, Zarate CA, Manji HK. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry. 2004;65(1): 10-21.
147. Lee KY, Ahn YM, Joo EJ, et al. No association of two common SNPs at position -1727 A/T, -50 C/T of GSK-3 beta polymorphisms with schizophrenia and bipolar disorder of Korean population. Neurosci Lett. 2006;395(2):175-178.
148. Michelon L, Meira-Lima I, Cordeiro Q, et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett. 2006;403(3):288-293.
149. Benedetti F, Bernasconi A, Lorenzi C, et al. A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett. 2004;355(1-2):37-40. doi:10.1016/j.neulet.203.10.021 PubMed (Pubitemid 38077179)
150. Roybal K, Theobold D, Graham A, et al. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A. 2007;104(15): 6406-6411.
151. Liu L, Foroud T, Xuei X, et al. Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. Psychiatr Genet. 2008;18(6):267-274.
152. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257-269.
153. Sklar P, Gabriel SB, McInnis MG, et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus: brain-derived neutrophic factor. Mol Psychiatry. 2002;7(6): 579-593.
154. Rybakowski JK, Borkowska A, Czerski PM, et al. Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disord. 2003;5(6):468-472.
155. Müller DJ, de Luca V, Sicard T, et al. Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. Br J Psychiatry. 2006;189(4):317-323.
156. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics. 2008;9(11):1595-1603.
157. Sarchiapone M, Carli V, Roy A, et al. Association of polymorphism (Val66Met) of brain-derived neurotrophic factor with suicide attempts in depressed patients. Neuropsychobiology. 2008;57(3):139-145.